Previous 10 | Next 10 |
Looking To Add Biotech Stocks To Your Watchlist? 3 Making Moves This Week It has clearly been the year of biotech stocks in the stock market. Investors and biotech companies alike will likely agree. Most of the top biotech stocks have seen massive rallies throughout this yea...
Arvinas (ARVN) initiates an underwritten pubic offering of $250M of its common stock. Price, size and terms are yet to be determined.Underwriters' overallotment option is to purchase up to an additional $37.5M of its common stock.Previously: Arvinas gains on protein degrader data (Dec. 1...
Gainers: BioCardia (BCDA) +102%.Arvinas (ARVN) +91%.Rubius Therapeutics (RUBY) +56%.Veru (VERU) +48%.AnPac Bio-Medical Science (ANPC) +45%.Homology Medicines (FIXX) +32%.ReneSola (SOL) +32%.Alexion Pharmaceuticals (ALXN) +31%.BioLineRx (BLRX) +30%.Big Rock Partners Acquisition (BRPA...
Gainers: Arvinas (ARVN) +97%, Rubius Therapeutics (RUBY) +95%, AnPac Bio-Medical Science (ANPC) +67%, Veru (VERU) +46%, BioCardia (BCDA) +31%.Losers: Aerpio Pharmaceuticals (ARPO) -47%, SELLAS Life Sciences (SLS) -27%, Greenwich Life...
Arvinas (ARVN) soars 97% in premarket after it says interim Phase 1 data for ARV-471 show evidence of anti-tumor activity and robust efficacy signals in heavily pretreated patients with locally advanced or metastatic ER positive / HER2 negative breast cancer.Data showed one confirme...
AnPac Bio-Medical Science (ANPC) +99% as company makes significant progress in detecting pre-cancer diseases.Arvinas (ARVN) +74% after releasing interim clinical data of PROTAC® protein degraders.Veru (VERU) +57% on positive phase 2 clinical trial results for Enobosarm.Syn...
– ARV-471 demonstrates evidence of anti-tumor activity, and potential for best-in-class safety, and estrogen receptor (ER) degradation profile and robust efficacy signals in a heavily pretreated patient population – – Initiation of a combination trial of ARV...
– Event to be webcast live on Monday, December 14, 2020 at 8:00 a.m. ET – NEW HAVEN, Conn., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
During a strong uptrend, certain stocks will be under distribution or show signs of weakness. These will lead on the downside, when the market turns. Four stocks in this category are WWE, COHR, EYEN, and ARVN. The market is quite strong and approaching new highs from a couple of weeks ago...
NEW HAVEN, Conn., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming virtual investor conferences: ...
News, Short Squeeze, Breakout and More Instantly...
Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial Officer Company is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential...
– Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (...
- Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ann...